📄 medicine

Predictive Value of METS-IR for Type 2 Diabetes Risk and Its Translational Relevance to Obesity-Associated MASLD: A Systematic Review and Meta-Analysis

This systematic review and meta-analysis of six studies involving nearly 169,000 participants demonstrates that a high METS-IR score is robustly associated with a 3.65-fold increased risk of type 2 diabetes, supporting its utility as a non-invasive screening tool for risk stratification in individuals with obesity-associated MASLD.

Original authors: Luis Jesuino de Oliveira Andrade, Gabriela Correia Matos de Oliveira, Raymundo Paraná, Osmário Jorge de Mattos Salles, Carlos Alberto Menezes, Luis Matos de Oliveira

Published 2026-07-28

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Luis Jesuino de Oliveira Andrade, Gabriela Correia Matos de Oliveira, Raymundo Paraná, Osmário Jorge de Mattos Salles, Carlos Alberto Menezes, Luis Matos de Oliveira

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine your body as a bustling city where energy (sugar) is the currency and insulin is the traffic cop directing it into cells. Sometimes, the roads get clogged, and the traffic cop stops responding to the cars piling up at the gates. This is called insulin resistance. When this happens, sugar builds up in the bloodstream, which can eventually lead to Type 2 Diabetes, a condition where the body struggles to manage its own energy.

But here's the twist: this traffic jam doesn't just happen in the streets; it also clogs up the city's main warehouse, the liver. When too much fat gets stored there, the liver becomes sluggish and inflamed. This condition is now known as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). It's like a warehouse overflowing with boxes until it can't function properly. Because the liver and the blood sugar system are best friends, a clogged liver often means a clogged sugar system, too. Doctors need a way to spot people whose "traffic" is about to crash before the accident happens, but the usual tests can be expensive or complicated. This is where a new, simple math trick called METS-IR comes in.

The Paper's Big Discovery: A Simple Math Trick for a Big Problem

In this study, a team of researchers decided to play detective with a specific question: Can we use a simple number called METS-IR to predict who is most likely to get Type 2 Diabetes?

Think of METS-IR as a "Metabolic Weather Forecast." Instead of needing a fancy, expensive machine to measure how well your body handles sugar (which is like hiring a private meteorologist), METS-IR is a formula you can calculate using four things your doctor already checks at a regular check-up: your fasting blood sugar, your triglycerides (a type of fat in your blood), your body mass index (BMI), and your "good" cholesterol (HDL). It's like checking the temperature, humidity, wind speed, and pressure to predict a storm, but for your metabolism.

The researchers gathered data from six different studies involving nearly 169,000 people from Mexico, China, and Iran. They wanted to see if people with the highest METS-IR scores were more likely to develop diabetes than those with the lowest scores.

The Verdict:
The results were loud and clear. People in the highest group for METS-IR had a 3.65 times higher risk of developing Type 2 Diabetes compared to those in the lowest group. To put that in perspective, if the lowest group had a 1 in 100 chance of getting diabetes, the highest group had a 3.65 in 100 chance. The math was so strong that the chance of this happening by accident was practically zero (a probability of 1.75 × 10⁻⁸).

Why This Matters for the "Liver People" (MASLD):
Here is the clever part of the story. The researchers didn't just stop at diabetes; they wanted to know if this math trick could also help people with obesity-associated MASLD (the clogged liver warehouse).

The paper explains that while none of the six studies specifically tested people who already had confirmed liver disease, the connection is biologically sound. Why? Because the same three things that clog the liver (too much body fat, bad blood fats, and sugar trouble) are exactly what the METS-IR formula measures. It's like saying, "If your house is on fire because of a short circuit in the kitchen, checking the kitchen's wiring is a great way to predict a fire, even if you haven't seen the flames yet."

The authors suggest that because METS-IR captures the exact same "troublemakers" that cause both liver fat and diabetes, it could be a fantastic, low-cost tool for doctors to screen people with obesity and liver issues. It helps identify who is on the fast track to diabetes so they can get help before the crash happens.

The Fine Print (How Sure Are They?):
The study is very confident in the link between high METS-IR and diabetes risk, calling the association "robust" and "consistent." However, they are careful to note that they haven't directly proven it works for people with confirmed liver disease yet. They are "inferring" or making a very educated guess based on how the body works. They also noticed that the strength of the risk varied a lot between different groups of people (some studies showed a 2x risk, others a 6x risk), but the direction was always the same: higher METS-IR means higher risk.

The Bottom Line:
This paper doesn't claim to have invented a cure, but it shines a spotlight on a simple, free calculator that doctors can use right now. It suggests that by keeping an eye on this "Metabolic Weather Forecast," we might be able to spot the storm clouds of diabetes and liver trouble early, giving people a chance to clear the roads before the traffic jam becomes a disaster.

Technical Summary: Predictive Value of METS-IR for Type 2 Diabetes Risk and Translational Relevance to Obesity-Associated MASLD

Problem Statement
Metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) share overlapping pathophysiological roots, primarily insulin resistance (IR) and visceral adiposity. While the Metabolic Score for Insulin Resistance (METS-IR) has emerged as a validated, non-insulin-based surrogate for insulin sensitivity—calculated using fasting glucose, triglycerides, body mass index (BMI), and HDL cholesterol—reported effect sizes regarding its association with incident T2DM have varied significantly across independent cohorts. Estimates have ranged from roughly twofold to more than sixfold risk increases. Crucially, no study had quantitatively pooled these estimates to provide a robust summary effect. Furthermore, while METS-IR captures the triad of adiposity, dyslipidemia, and dysglycemia driving both hepatic steatosis and diabetes, its specific applicability as a risk-stratification tool for individuals with obesity-associated MASLD lacked a synthesized evidence base.

Methodology
This systematic review and meta-analysis adhered to PRISMA 2020 guidelines. The authors searched PubMed/MEDLINE through July 2026 for studies meeting specific eligibility criteria:

Participants: Adult human populations.
Exposure: METS-IR calculated via the validated formula: $Ln[(2 \times \text{fasting glucose}) + \text{fasting triglycerides}] \times \text{BMI} / Ln(\text{HDL cholesterol})$ .
Outcome: Incident or prevalent T2DM defined by standard criteria (fasting glucose, HbA1c, physician diagnosis, or medication).
Data Requirements: Studies must report multivariable-adjusted hazard ratios (HR) or odds ratios (OR) with 95% confidence intervals (CI) comparing the highest versus lowest METS-IR quartile.

Six studies (totaling 168,993 participants from Mexico, China, and Iran) met the criteria. The analysis employed a random-effects meta-analysis (DerSimonian-Laird method) to pool log-transformed HRs/ORs. Heterogeneity was assessed using Cochran's Q and $I^2$ statistics. Sensitivity was evaluated via leave-one-out analysis, and methodological quality was assessed using the Newcastle-Ottawa Scale (NOS). Subgroup analyses were conducted based on study design (cohort vs. cross-sectional) and geographical region (China vs. non-China).

Key Results

Pooled Association: Individuals in the highest METS-IR quartile demonstrated a significantly elevated risk of T2DM compared to those in the lowest quartile. The pooled random-effects estimate was 3.65 (95% CI: 2.33–5.72; $P = 1.75 \times 10^{-8}$ ).
Heterogeneity: Substantial heterogeneity was observed ( $I^2 = 95.7\%$ ). This variation was attributed to differences in population characteristics (age, ethnicity, baseline risk), outcome ascertainment methods, follow-up duration, and covariate adjustment strategies.
Subgroup Findings:
- Study Design: Stratification by design showed that five longitudinal cohort studies yielded a pooled HR of 3.25, while the single cross-sectional study reported an OR of 6.23. The difference between designs was not statistically significant ( $P = 0.077$ ).
- Geography: Non-Chinese cohorts (Mexico and Iran) showed a highly consistent pooled estimate of 3.49 with zero residual heterogeneity ( $I^2 = 0.0\%$ ). Chinese cohorts showed a pooled estimate of 3.63 but with high internal heterogeneity ( $I^2 = 97.2\%$ ).
Robustness and Quality: Leave-one-out sensitivity analysis confirmed the pooled estimate remained stable (range: 3.24–4.21) regardless of which single study was excluded. All six included studies were rated as high methodological quality (NOS score $\ge$ 7/9).
Publication Bias: Visual inspection of the funnel plot showed no marked asymmetry, though formal statistical testing was not performed due to the small number of studies.

Translational Relevance to MASLD
The authors note a critical limitation: none of the included studies enrolled cohorts specifically pre-selected for imaging- or biopsy-confirmed MASLD. Consequently, the applicability of these pooled results to obesity-associated MASLD is indirect. The authors argue that this applicability rests on the established mechanistic overlap between MASLD, visceral/hepatic fat accumulation, and the components of METS-IR itself. The review posits that METS-IR serves as an indirect marker of the metabolic network connecting obesity, liver dysfunction, and pancreatic $\beta$ -cell exhaustion.

Significance and Claims
The paper claims that elevated METS-IR is consistently and robustly associated with a markedly increased risk of T2DM. The primary significance of this work lies in:

Quantitative Synthesis: Providing the first statistically weighted summary effect estimate for the METS-IR/T2DM association, moving beyond the variability of individual cohort reports.
Clinical Utility: Supporting METS-IR as an accessible, non-invasive screening tool for risk stratification. Because it relies on routine clinical variables (glucose, lipids, BMI) rather than insulin assays, it is feasible for widespread implementation in primary care and hepatology.
Translational Bridge: Offering a biological rationale for using METS-IR in obesity-associated MASLD populations to identify individuals at risk of metabolic decompensation before the onset of overt diabetes.

The authors conclude that while the evidence is of "moderate certainty" (due to the observational nature of the data and the lack of direct MASLD-confirmed cohorts), the findings provide compelling support for incorporating METS-IR into cardiometabolic risk assessment frameworks to facilitate early, precision-based preventive interventions.

The Paper's Big Discovery: A Simple Math Trick for a Big Problem

Technical Summary: Predictive Value of METS-IR for Type 2 Diabetes Risk and Translational Relevance to Obesity-Associated MASLD

More like this